<DOC>
	<DOCNO>NCT01572181</DOCNO>
	<brief_summary>The purpose study ass transplant-related mortality ( TRM ) one year allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) prepare `` reduce toxicity myeloablative '' condition regimen young patient ( child adolescent ) hematologic malignancy .</brief_summary>
	<brief_title>Study Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine Full Doses Intravenous Busulfan Pediatric Patients Not Eligible Standard Myeloablative Conditioning Regimens</brief_title>
	<detailed_description />
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion Criteria Children adolescent age 12 month 25 year Availability HLA identical family donor HLAmatched unrelated donor ( 10/10 9/10 mismatch level HLACw unrelated donor ) availability HLA match cord blood ( 5/6 6/6 ) Informed consent sign patient ( 1825 year ) patient 's legal representative , parent ( ) guardian ( cf p13 ) Diagnosis hematologic malignancy candidate alloHSCT , eligible standard conventional myeloablative conditioning regimen high risk toxicity . Are consider criterion noneligibility standard conventional myeloablative conditioning : history autologous allogeneic stem cell transplantation comorbidities medical history predictive prohibitive rate TRM toxicity use standard high dose chemotherapy / radiotherapy . Patient administer systemic chemotherapeutic drug ( include Gemtuzumab ) within 21 day prior trial enrollment start condition regimen . Hydroxyurea permit indicated control induction refractory disease , IT chemotherapy allow indicated maintenance treatment previously diagnose leptomeningeal disease , remission least 3 month prior enrollment study . Active infection . Protocol PI final arbiter uncertainty regard whether previous infection resolve . Children adolescents old 12 month 25 year A donor HLA mismatch level one locus . Poor performance status ( Lansky &lt; 50 % ) Life expectancy severely limited concomitant illness expect &lt; 12 week . Left ventricular ejection fraction &lt; 30 % . Uncontrolled arrhythmias symptomatic cardiac disease . Symptomatic pulmonary disease . FEV1 , FVC DLCO &lt; 30 % expect corrected hemoglobin . Creatinine clearance le 30 mL/m per 1.73 m2 require dialysis Evidence chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Study Chairman consider liver biopsy . Effusion ascites &gt; 1L prior drainage . HIVpositive . Female pregnancy Absence effective contraception among boys girl childbearing potential ( contraception continue 6 month stop treatment ) Breastfeeding Patient 's legal representative , parent ( ) guardian able sign inform consent . child 's refusal Hypersensitivity rabbit protein , active substance excipients experimental product</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>